Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Patent
1997-01-21
1998-06-30
Jones, W. Gary
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
536 231, 536 243, C07K 1400, C07H 2100
Patent
active
057735794
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The invention relates to genes and proteins specific for certain cancers and methods for their detection.
BACKGROUND OF THE INVENTION
Lung cancer is the most common form of cancer in the world. Estimates for the year 1985 indicate that there were about 900,000 cases of lung cancer worldwide. (Parkin, et al., "Estimates of the worldwide incidence of eighteen major cancers in 1985," Int J Cancer 1993; 54:594-606). For the United States alone, 1993 projections placed the number of new lung cancer cases at 170,000, with a mortality of about 88%. (Boring, et al., "Cancer statistics," CA Cancer J Clin 1993; 43:7-26). Although the occurrence of breast cancer is slightly more common in the United States, lung cancer is second behind prostate cancer for males and third behind breast and colorectal cancers for women. Yet, lung cancer is the most common cause of cancer deaths.
The World Health Organization classifies lung cancer into four major histological types: (1) squamous cell carcinoma (SCC), (2) adenocarcinoma, (3) large cell carcinoma, and (4) small cell lung carcinoma (SCLC). (The World Health Organization, "The World Health Organization histological typing of lung tumours," Am J Clin Pathol 1982; 77:123-136). However, there is a great deal of tumor heterogeneity even within the various subtypes, and it is not uncommon for lung cancer to have features of more than one morphologic subtype. The term non-small cell lung carcinoma (NSCLC) includes squamous, adenocarcinoma and large cell carcinomas.
Typically, a combination of X-ray and sputum cytology is used to diagnose lung cancer. Unfortunately, by the time a patient seeks medical help for their symptoms, the cancer is at such an advanced state it is usually incurable. Cancer Facts and Figures (based on rates from NCI SEER Program 1977-1981), New York: American Cancer Society, 1986). Routine large-scale radiologic or cytologic screening of smokers has been investigated. Studies concluded that cytomorphological screening did not significantly reduce the mortality rate from lung cancer and was not recommended for routine use. ("Early lung cancer detection: summary & conclusions," Am Rev Respir Dis 1984; 130:565-70). However, in a subpopulation of patients where the cancer is diagnosed at a very early stage and the lung is surgically resectioned, there is a 5-year survival rate of 70-90%. (Flehinger, et al., "The effect of surgical treatment on survival from early lung cancer," Chest; 1992, 101:1013-1018; Melamed, et al., "Screening for early lung cancer: results of the Memorial Sloan-Kettering Study in New York," Chest; 1984 86:44-53). Therefore, research has focused on early detection of tumor markers before the cancer becomes clinically apparent and while the cancer is still localized and amenable to therapy.
The identification of antigens associated with lung cancer has stimulated considerable interest because of their use in screening, diagnosis, clinical management, and potential treatment of lung cancer. International workshops have attempted to classify the lung cancer antigens into 15 possible clusters that may define histologic origins. (Souhami, et al., "Antigens of lung cancer: results of the second international workshop on lung cancer antigens," JNCI 1991; 83:609-612). As of 1988, more than 200 monoclonal antibodies (MAb) have been reported to react with human lung tumors. (Radosevich, et al., "Monoclonal antibody assays for lung cancer," In: Cancer Diagnosis in Vitro Using Monoclonal Antibodies. Edited by H. A. Kupchik. New York: Marcel Dekker, 1988).
MAbs for lung cancer were first developed to distinguish NSCLC from SCLC. (Mulshine, et al., "Monoclonal antibodies that distinguish nonsmall-cell from small-cell lung cancer," J Immunol 1983; 121:497-502). In most cases, the identity of the cell surface antigen with which a particular antibody reacts is not known, or has not been well characterized. (Scott, et al., "Early lung cancer detection using monoclonal antibodies," In: Lung Cancer. Edited by J. A. Roth, J. D. Cox, and W.
REFERENCES:
patent: 4816402 (1989-03-01), Rosen et al.
patent: 4990454 (1991-02-01), Yachi et al.
patent: 5134075 (1992-07-01), Hellstrom et al.
patent: 5185432 (1993-02-01), Hellstrom et al.
patent: 5200508 (1993-04-01), Nilaver et al.
Aldred et al., Biochemistry 30(2):569-575 (1991).
Montgomery et al., Genomics 11(14):835-848 (1991).
Anastasi, et al., "Direct correlation of cytogenetic findings with cell morphology using in situ hybridization: an analysis of suspicious cells in bone morrow specimens of two patients completing therapy for acute lymphoblastic leukemia," Blood 77:2456-2462 (1991).
Altschul, et al., "Basic local alignment search tool," J. Molecular Biol 215:403-410 (1990).
Birrer, et al., "Application of molecular genetics to the early diagnosis and screening of lung cancer," Cancer Research (supplement) 52:2658s-2664s (1992).
Boring, et al., "Cancer statistics,1993," CA Cancer J Clin 43:7-26 (1993).
Chirgwin, et al., "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease," Biochem 18:5294-5299 (1979).
Diez, et al., "Prognostic significance of serum CA 125 antigen assay in patients with non-small cell lung cancer," Cancer 73:1368-1376 (1994).
Flehinger, et al., "The effect of surgical treatment on survival from lung cancer: implications for screening," Chest 101:1013-1018 (1992).
Gray, JW and Pinkel, D, "Molecular cytogenetics in human cancer diagnosis," Cancer (supplement) 69:1536-1542 (1992).
Hasegawa, et al., "Nonspecific crossreacting antigen (NCA) is a major member of the carcinoembryonic antigen (CEA)-related gene family expressed in lung cancer," British J Cancer 67:58-65 (1993).
von Heijne, G., "A new method for predicting signal sequence cleavage sites," Nucleic Acid Research 14:4683-4690 (1986).
Kern, et al., "p185.sup.neu Expression in human lung adenocarcinomas predicts shortened survival," Cancer Research 50:5184-5191 (1990).
Kim, et al., "Interphase cytogenetics in paraffin sections of lung tumors by non-isotopic in situ hybridization," Am J Path 142:307-317 (1993).
Kunkel, TA, "Rapid and efficient site-specific mutagenesis without phenotypic selection," Proc Natl Acad Sci USA 82:488-492 (1985).
Margolis, et al., "Serum tumor markers in non-small cell lung cancer," Cancer 73:605-609 (1994).
Melamed, et al., "Screening for early lung cancer: results of the Memorial Sloan-Kettering study in New York," Chest 86:44-53 (1984).
Mitsudomi, et al., "p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features," Oncogene 7:171-180 (1992).
Mori, et al., "The significance of carbonic anyhdrase expression in human colorectal cancer," Gastroenterology 105:820-826 (1993). Abstract Only.
Mulshine, et al., "Section 22.5 Applications of monoclonal antibodies in the treatment of solid tumors," Biologic Therapy of Cancer, VT DeVita, S. Hellman, SA Rosenberg (ed), JB Lippencott Co., New York, pp. 563-588 (1991).
Parkin, et al., "Estimates of the worldwide incidence of eighteen major cancers in 1985," Int J Cancer 54:594-606 (1993).
Radosevich, et al., "Monoclonal antibody assays for lung cancer," Cancer Diagnosis In Vitro Using Monoclonal Antibodies, H. Kupchik (ed.), Marcel Dekker, Inc., New York, pp. 101-121 (1988).
Schepart, BS and Margolis, ML, "Monoclonal antibody-mediated detection of lung cancer antigens in serum," Am Rev Respir Dis 138:1434-1438 (1988).
Scott, et al., "Early lung cancer detection using monoclonal antibodies," Lung Cancer, JA Roth, JD Cox, and WK Hong (eds), Blackwell Scientific Publications, Boston, pp. 310-323 (1993).
Skonier, et al., "cDNA cloning and sequence analysis of .beta.ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-.beta.," DNA Cell Biology 11:511-522 (1992).
Smith, DB and Johnson, KS, "Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase," Gene 67:31-40 (1988).
Souhami, et al.,
Bollon Arthur P.
Torczynski Richard M.
Cytoclonal Pharmaceutics, Inc.
Jones W. Gary
Whisenant Ethan
LandOfFree
Lung cancer marker does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lung cancer marker, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lung cancer marker will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1860836